The 10-second takeaway
For the quarter ended Dec. 31 (Q4), AmSurg beat expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly, and GAAP earnings per share improved significantly.
Gross margins expanded, operating margins dropped, and net margins were steady.
AmSurg logged revenue of $223.3 million. The eight analysts polled by S&P Capital IQ predicted revenue of $213.7 million on the same basis. GAAP reported sales were 26% higher than the prior-year quarter's $177.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.46. The nine earnings estimates compiled by S&P Capital IQ averaged $0.46 per share on the same basis. GAAP EPS of $0.44 for Q4 were 26% higher than the prior-year quarter's $0.35 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 85.9%, 2,990 basis points better than the prior-year quarter. Operating margin was 29.3%, 390 basis points worse than the prior-year quarter. Net margin was 6.1%, about the same as the prior-year quarter.
Next quarter's average estimate for revenue is $215.5 million. On the bottom line, the average EPS estimate is $0.47.
Next year's average estimate for revenue is $909 million. The average EPS estimate is $1.98.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 142 members rating the stock outperform and eight members rating it underperform. Among 60 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 57 give AmSurg a green thumbs-up, and three give it a red thumbs-down.
Over the decades, small-cap stocks like AmSurg have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add AmSurg to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.